MedPath

Observational Study to Evaluate Peripheral IntraVenous Analysis (PIVA) in Euvolemic, Hypovolemic, and Hypervolemic Emergency Department Patients

Terminated
Conditions
Hypervolemia
Congestive Heart Failure
Septic Shock
Acute Heart Failure
Infection
Hypovolemia
Interventions
Procedure: Peripheral Intravenous Analysis (PIVA)
Procedure: Non-invasive fluid response measure
Diagnostic Test: Passive leg raise (PLR)
Registration Number
NCT03736421
Lead Sponsor
Beth Israel Deaconess Medical Center
Brief Summary

The overall goal of this multicenter project is to characterize the expected normal range of Peripheral IntraVenous Volume Analysis (PIVA) values during a euvolemic state, and how those ranges may be altered by comorbidities; the relationship between PIVA and intravenous volume administration during resuscitation of infected patients with presumed hypovolemia; and, the relationship between PIVA and volume decreases during diuresis in acute heart failure patients with hypervolemia.

Detailed Description

The determination of volume status remains a clinical challenge in medicine. Patients may develop hypovolemia (too little fluids in the vascular space) due to conditions such as hemorrhage, dehydration, or infection with vascular leak. Alternatively, patients may become hypervolemic (too much fluids in the vascular space), due to conditions such as heart failure, renal failure, or iatragenic over-resuscitation all of which overwhelm the kidney's ability to regulate intravascular volume status. In clinical practice, clinicians strive to return patients to euvolemia (the "right" volume status) through the administration of intravenous fluids or diuretics which remove fluids to achieve homeostasis. While there are a number of proposed clinical exam findings (e.g. dry mucous membranes or skin turgor), measurements (e.g. central venous pressure), or laboratory tests (e.g. blood urea nitrogen), none are precise or universally accepted as reliable methodologies to assess volume status.

The goal of this study is to perform a prospective observational study on three distinct cohorts during ED presentation to assess the variability and performance of PIVA in tracking volume status.

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
50
Inclusion Criteria
  • Age > 18 years old
  • Assessed as "euvolemic" by treating physician
Exclusion Criteria
  • History of any type of decreased oral intake or volume loss (e.g. diarrhea, vomiting, etc)

  • History of a fever

  • History of bleeding

  • Any acute illness expected to alter volume

  • Known or suspected pregnancy

  • Active irregular heart rhythm

  • In the opinion of the treating physician, no anticipated intravenous fluid administration

  • History of chronic or end stage renal disease

  • Liver failure

  • History of Acute heart failure

  • Presence of abnormal vital signs (90 < HR < 60; 180 < SBP < 110, respiratory rate > 20, pulse ox < 92% or need for supplemental oxygen, 99.0 < temperature < 96).

    2 additional group will be included in this euvolemic group

  • Non-elderly patients (age < 50 year) without any comorbid illnesses and

  • Age >65

  • Diabetes on medications

  • Hypertension on medications

  • Vascular disease defined by history of peripheral vascular disease, stroke, MI

Note: patients that receive >250 cc of IVF will be excluded from analysis.

Infection Cohort (Presumed Hypovolemia)

Inclusion Criteria:

  • Age > 18 years old
  • An accessible intravenous catheter is in place
  • Known or suspected infection as assessed by the clinical team
  • Intention to admit to the hospital
  • Anticipated administration of intravenous fluids per clinical team

Exclusion Criteria:

  • Clinical exam consistent with volume overload
  • Known or suspected pregnancy
  • Patients with a history of chronic renal insufficiency or end-stage renal disease
  • Patients with a history of acute heart failure

Acute Heart Failure (Hypervolemic cohort)

Inclusion Criteria:

  • Age > 17 years old
  • An accessible intravenous catheter is in place
  • Primary clinical diagnosis of CHF
  • Meet 2 of the three criterion:
  • X-ray diagnosis
  • Elevated bnp from known baseline
  • Clinical diagnosis
  • Received or intent to administer a diuretic agent
  • Intent to admit to the hospital for anticipated > 24 hour period

Exclusion Criteria:

  • History of any type of decreased oral intake or volume loss (e.g. diarrhea, vomiting, etc)
  • History of a fever
  • History of bleeding
  • Known or suspected pregnancy
  • Active irregular heart rhythm
  • History of dialysis dependent end stage renal disease

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Acute Heart FailureNon-invasive fluid response measureThis cohort will have a diagnosis of CFH who are being admitted to the hospital. These patients will be followed during their hospital course.
Infection CohortPeripheral Intravenous Analysis (PIVA)This cohort are subjects with suspected infection, enriched to contain sepsis patients.
Infection CohortPassive leg raise (PLR)This cohort are subjects with suspected infection, enriched to contain sepsis patients.
Acute Heart FailurePeripheral Intravenous Analysis (PIVA)This cohort will have a diagnosis of CFH who are being admitted to the hospital. These patients will be followed during their hospital course.
Acute Heart FailurePassive leg raise (PLR)This cohort will have a diagnosis of CFH who are being admitted to the hospital. These patients will be followed during their hospital course.
Control CohortPeripheral Intravenous Analysis (PIVA)This cohort is recruited to help to define what a "normal" PIVA value should be during a state of presumed euvolemia.
Control CohortPassive leg raise (PLR)This cohort is recruited to help to define what a "normal" PIVA value should be during a state of presumed euvolemia.
Infection CohortNon-invasive fluid response measureThis cohort are subjects with suspected infection, enriched to contain sepsis patients.
Primary Outcome Measures
NameTimeMethod
Association between PIVA measurement and fluid status (net gain vs net loss)Baseline to 6 hours for euvolemic and hypovolemic cohort, and baseline to 72 hours for hypervolemic cohort

Change in fluid status over the first 6 hours as measured by weight and urine output and pressure status from the Edwards transducer

Secondary Outcome Measures
NameTimeMethod
Response to Passive leg raiseFor the euvolemic cohort, baseline to 2 hours; For hypovolemic, cohort baseline to 6 hours; for the hypervolemic cohort, baseline up to 72 hours

Compute the change in PIVA measurement between before and after the passive leg raise challenge within each cohort

Association between PIVA and non-invasive monitoring responsiveness to passive leg raiseBaseline up to 72 hours

Compare change in PIVA measurements to non-invasive monitoring measurements before and after passive leg raise and before and after fluid boluses

Trial Locations

Locations (3)

St. Vincent Hospital

🇺🇸

Worcester, Massachusetts, United States

Beth Israel Medical Center

🇺🇸

Boston, Massachusetts, United States

University of Washington

🇺🇸

Seattle, Washington, United States

© Copyright 2025. All Rights Reserved by MedPath